Gathering last week in Australia, the community continued its years-long push towards increased clinical relevance and integration with other omics disciplines.
The instrument's ability to run in negative-ion mode allows it to move beyond its traditional focus on proteins and into the analysis of other analyte classes.
The approach uses miniaturized sample prep and isobaric tagging and can identify up to 2,300 proteins in single cells and analyze around 100 cells per day.
Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.
Developed using the center's "industrialized" proteomics workflow, the panel identified patients up to a year before their diagnosis with 89 percent accuracy.
The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.
The study authors said that the technique could help researchers better prioritize which of the vast number of protein PTMs to investigate more thoroughly.
The firm had revenues of $6.32 billion in Q2, up 4 percent from $6.08 billion last year and just beating the average Wall Street estimate of $6.3 billion.
At the recent ASMS annual meeting, vendors including Bruker, Sciex, and Thermo Fisher Scientific presented new versions of the fast-growing mass spec technique.
The firm, Phenomix Sciences, anticipates that its test will help drive adoption of medications for obesity at a time when patients are reluctant to take them.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
